Forest Lab's (NYSE: FRX) Teflaro is listed as a phase III "one to watch" by Thomson Reuters Pharma.
Teflaro is used to treat bacterial pneumonia.
From the report: "Teflaro is an injectable formulation of the broad-spectrum antibiotic ceftaroline fosamil from Forest Laboratories, which acquired the worldwide rights to the drug after its acquisition of Cerexa in 2007. Teflaro received approval from the FDA in October 2010 for the treatment of community-acquired bacterial pneumonia (CABP), including those cases caused by multidrug-resistant Streptococcus pneumoniae, and skin and skin structure infections (SSSIs), including those caused by methicillin-resistant Staphylococcus aureus.
Both bacterial CABP and SSSI are serious, potentially life-threatening
conditions, and new treatments are needed constantly, particularly as
bacteria resistance to existing antibiotics continues to increase.
Phase III trials showed that Teflaro had a similar response and cure rate
to ceftriaxone in CABP patients and was as effective as vancomycin plus
aztreonam against SSSIs."
Also mentioned in the report:
Haleven, from Eisai (Metastatic breast cancer)
Kombiglyze XR, from AstraZeneca/Bristol Myers Squibb (Type 2 diabetes)
Brilique, from AstraZeneca (Acute coronary syndrome)
Ruconest, from Pharming/Esteve (Hereditary angioedema)
The full report is available at
http://thomsonreuters.com/content/science/pdf/ls/pharma_matters/the_ones_to_watch.pdf
No comments:
Post a Comment